Results 191 to 200 of about 145,153 (301)

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, Accepted Article.
Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz, Seza Ozen, Hacer N. Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet E. Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet O. Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Cutaneous Mucormycosis Clinically Mimicking Necrotizing Fasciitis in a Patient Without Active Immunosuppression. [PDF]

Clin Case Rep
İnan AÖ, Yıldız Zengin N, Pehlevan A, Ceylan E, Uyar Güleç G, Öncü S.   +5 more
europepmc   +1 more source

A novel nerve block and anatomy workshop for emergency medicine residents: A pilot study

Anatomical Sciences Education, EarlyView.
Abstract Construct a workshop for emergency medicine (EM) residents to learn ultrasound‐guided regional anesthesia (UGRA) procedures and build confidence in performing those procedures. Use pre‐ and post‐workshop knowledge and confidence surveys to determine workshop effectiveness.
Geoffery D. Fernquist, Derek Harmon, Lauren D. Branditz, Andrew Kendle, Melissa M. Quinn   +4 more
wiley   +1 more source

Review and new therapeutic alternatives for the treatment of cutaneous Leishmaniasis

Podeu consultar el llibre complet a: http://hdl.handle.net/2445/63704Leishmaniasis comprises a group of diseases caused by protozoa of the genus Leishmania and has two basic clinical forms, visceral Leishmaniasis and cutaneous Leishmaniasis. The clinical
Pujol Brugués, Alba, Riera Lizandra, Ma. Cristina   +1 more
core  

Case Report: Nasal swelling and ulceration as a unique immune-related cutaneous adverse event of atezolizumab in small cell lung cancer. [PDF]

Front Immunol
Yang J, Du X, Liu H, Hao Y.
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Case Report: Cutaneous niche-restricted malignant phenotypes in PTCL-NOS revealed by single-cell sequencing. [PDF]

Front Oncol
Zhang S, Li Z, Lin Y, Sun X, Qiao M, Si X.   +5 more
europepmc   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report. [PDF]

Front Oncol
Wu R, Chen X, Li T, Zhang Y, Ling X.
europepmc   +1 more source

Clinical Images: Subcutaneous panniculitis‐like T cell lymphoma

Arthritis &Rheumatology, EarlyView.
S Chambers, CN Myrdal, VP Werth
wiley   +1 more source